XOMA Corporation Company Profile (NASDAQ:XOMA)

About XOMA Corporation

XOMA Corporation logoXOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: XOMA
  • CUSIP: 98419J10
Key Metrics:
  • Previous Close: $5.15
  • 50 Day Moving Average: $4.66
  • 200 Day Moving Average: $3.43
  • 52-Week Range: $6,047,000.00 - $0.34
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.92
  • P/E Growth: -0.03
  • Market Cap: $31.81M
  • Outstanding Shares: 6,047,000
  • Beta: 3.56
Profitability:
  • Net Margins: -20.10%
  • Return on Assets: -24.11%
Debt:
  • Debt-to-Equity Ratio: -1.05%
  • Current Ratio: 0.98%
  • Quick Ratio: 0.98%
Additional Links:
Companies Related to XOMA Corporation:

Analyst Ratings

Consensus Ratings for XOMA Corporation (NASDAQ:XOMA) (?)
Ratings Breakdown: 6 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $8.00 (52.09% upside)

Analysts' Ratings History for XOMA Corporation (NASDAQ:XOMA)
Show:
DateFirmActionRatingPrice TargetDetails
2/1/2017Cowen and CompanyReiterated RatingHoldView Rating Details
1/5/2017WedbushReiterated RatingNeutral$14.00View Rating Details
11/16/2016Ladenburg Thalmann Financial ServicesReiterated RatingNeutralView Rating Details
8/5/2016Jefferies Group LLCReiterated RatingHoldView Rating Details
3/12/2016Piper Jaffray CompaniesReiterated RatingHoldView Rating Details
3/11/2016Royal Bank Of CanadaReiterated RatingSector Perform$2.00View Rating Details
9/15/2015Deutsche Bank AGReiterated RatingSellView Rating Details
6/29/2015Susquehanna Bancshares IncDowngradePositive -> NeutralView Rating Details
5/5/2015Credit Suisse GroupReiterated RatingNeutral$5.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for XOMA Corporation (NASDAQ:XOMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
11/9/2016Q3($2.40)($2.08)$1.29 million$0.64 millionViewN/AView Earnings Details
8/3/2016($0.12)($0.13)$0.84 million$0.40 millionViewN/AView Earnings Details
5/4/2016($0.12)($0.07)ViewN/AView Earnings Details
3/9/2016Q415($0.15)$0.21$4.01 million$48.18 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.18)$3.55 million$2.10 millionViewListenView Earnings Details
8/6/2015Q215($0.18)($0.20)$4.38 million$2.54 millionViewListenView Earnings Details
5/7/2015Q115($0.16)($0.19)$4.31 million$2.65 millionViewListenView Earnings Details
3/11/2015Q414($0.14)($0.12)$10.70 million$4.30 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)($0.17)$7.00 million$5.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)$5.32 million$5.97 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.23)$7.40 million$3.41 millionViewN/AView Earnings Details
3/4/2014Q413($0.19)($0.55)$7.92 million$8.45 millionViewN/AView Earnings Details
11/7/2013Q313($0.18)($0.21)$7.87 million$6.31 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.21)$9.30 million$7.20 millionViewN/AView Earnings Details
11/7/2012Q312($0.21)($0.39)$11.69 million$7.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for XOMA Corporation (NASDAQ:XOMA)
Current Year EPS Consensus Estimate: $-8.39 EPS
Next Year EPS Consensus Estimate: $-5.70 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.10)($0.10)($0.10)
Q2 20162($0.15)($0.09)($0.12)
Q3 20162($0.14)($0.10)($0.12)
Q4 20162($2.68)($2.01)($2.35)
Q1 20171($0.75)($0.75)($0.75)
Q2 20171($2.57)($2.57)($2.57)
Q3 20171($2.57)($2.57)($2.57)
Q4 20171($2.56)($2.56)($2.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for XOMA Corporation (NASDAQ:XOMA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for XOMA Corporation (NASDAQ:XOMA)
Insider Ownership Percentage: 3.92%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2017James R NealVPSell195$4.52$881.40View SEC Filing  
1/9/2017James R. NealVPSell125$5.15$643.75View SEC Filing  
12/21/2016John VarianDirectorSell13,549$5.75$77,906.75View SEC Filing  
12/21/2016Patrick J Md Phd ScannonVPSell3,230$5.75$18,572.50View SEC Filing  
11/1/2016James R. NealVPSell150$5.25$787.50View SEC Filing  
10/7/2016James R. NealVPSell2,500$0.45$1,125.00View SEC Filing  
3/22/2016John VarianCEOSell81,022$0.78$63,197.16View SEC Filing  
3/22/2016Patrick J Md Phd ScannonVPSell14,785$0.78$11,532.30View SEC Filing  
3/22/2016Paul D RubinCMOSell24,194$0.78$18,871.32View SEC Filing  
2/1/2016Patrick J Md Phd ScannonVPSell8,000$1.01$8,080.00View SEC Filing  
12/28/2015Patrick J Md Phd ScannonVPSell8,000$1.37$10,960.00View SEC Filing  
11/23/2015Patrick J Md Phd ScannonVPSell8,000$1.35$10,800.00View SEC Filing  
10/26/2015Patrick J Md Phd ScannonVPSell8,000$1.04$8,320.00View SEC Filing  
7/22/2015Bros. Advisors Lp BakerInsiderSell11,000,000$1.09$11,990,000.00View SEC Filing  
7/15/2015John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
7/15/2015Paul D RubinCMOSell5,000$4.60$23,000.00View SEC Filing  
7/10/2015Paul D RubinCMOSell33,400$4.55$151,970.00View SEC Filing  
6/15/2015John VarianCEOSell10,000$3.64$36,400.00View SEC Filing  
4/15/2015John VarianCEOSell10,000$3.86$38,600.00View SEC Filing  
3/23/2015Paul D RubinCMOSell32,742$3.94$129,003.48View SEC Filing  
3/16/2015John VarianCEOSell10,000$3.72$37,200.00View SEC Filing  
2/2/2015Patrick J Md Phd ScannonVPSell5,000$3.52$17,600.00View SEC Filing  
1/15/2015John VarianCEOSell10,000$3.46$34,600.00View SEC Filing  
1/6/2015Bros. Advisors Lp BakerDirectorSell2,215,400$3.81$8,440,674.00View SEC Filing  
1/2/2015Patrick J Md Phd ScannonVPSell5,000$3.55$17,750.00View SEC Filing  
12/30/2014Bros. Advisors Lp BakerDirectorSell744,000$3.67$2,730,480.00View SEC Filing  
12/19/2014Bros. Advisors Lp BakerDirectorSell1,605,100$4.26$6,837,726.00View SEC Filing  
12/16/2014Bros. Advisors Lp BakerDirectorSell1,033,800$4.46$4,610,748.00View SEC Filing  
12/15/2014John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
12/15/2014Paul D RubinCMOSell1,600$4.63$7,408.00View SEC Filing  
12/9/2014Bros. Advisors Lp BakerDirectorSell392,353$4.62$1,812,670.86View SEC Filing  
12/4/2014Bros. Advisors Lp BakerDirectorSell2,372,206$4.79$11,362,866.74View SEC Filing  
12/1/2014Patrick J Md Phd ScannonVPSell5,000$5.51$27,550.00View SEC Filing  
11/26/2014James R NealVPSell1,678$5.67$9,514.26View SEC Filing  
11/24/2014James R NealVPSell1,032$5.03$5,190.96View SEC Filing  
11/20/2014Paul D RubinCMOSell5,000$4.55$22,750.00View SEC Filing  
11/13/2014Fred KurlandCFOSell8,773$3.89$34,126.97View SEC Filing  
11/13/2014James R NealVPSell4,387$3.89$17,065.43View SEC Filing  
11/13/2014John VarianCEOSell58,844$3.89$228,903.16View SEC Filing  
11/3/2014Patrick J Md Phd ScannonVPSell5,000$4.33$21,650.00View SEC Filing  
10/28/2014Paul D RubinCMOSell5,000$4.57$22,850.00View SEC Filing  
10/15/2014John VarianCEOSell10,000$3.87$38,700.00View SEC Filing  
10/1/2014Patrick J Md Phd ScannonVPSell5,000$4.09$20,450.00View SEC Filing  
9/15/2014John VarianCEOSell10,000$4.56$45,600.00View SEC Filing  
9/15/2014Paul D RubinCMOSell5,000$4.59$22,950.00View SEC Filing  
9/4/2014Paul D RubinCMOSell10,000$4.56$45,600.00View SEC Filing  
9/2/2014Patrick J Md Phd ScannonVPSell5,000$4.31$21,550.00View SEC Filing  
8/18/2014Paul D RubinCMOSell26,748$4.34$116,086.32View SEC Filing  
8/15/2014Fred KurlandCFOSell10,401$4.31$44,828.31View SEC Filing  
8/15/2014John VarianCEOSell64,823$4.30$278,738.90View SEC Filing  
8/15/2014Patrick J Md Phd ScannonVPSell5,871$4.31$25,304.01View SEC Filing  
8/1/2014Patrick J Md Phd ScannonVPSell5,000$3.83$19,150.00View SEC Filing  
7/15/2014John VarianCEOSell10,000$4.03$40,300.00View SEC Filing  
7/1/2014Patrick J Md Phd ScannonVPSell5,000$4.68$23,400.00View SEC Filing  
6/16/2014John VarianCEOSell10,000$4.54$45,400.00View SEC Filing  
6/16/2014Paul D RubinCMOSell11,580$4.54$52,573.20View SEC Filing  
5/28/2014Paul D RubinCMOSell1,785$4.22$7,532.70View SEC Filing  
5/15/2014John VarianCEOSell10,000$3.55$35,500.00View SEC Filing  
4/15/2014John VarianCEOSell10,000$4.06$40,600.00View SEC Filing  
3/18/2014Fred KurlandCFOSell5,915$6.32$37,382.80View SEC Filing  
3/18/2014John VarianCEOSell21,329$6.32$134,799.28View SEC Filing  
3/18/2014Patrick Md Phd ScannonVPSell3,419$6.32$21,608.08View SEC Filing  
3/18/2014Paul RubinCMOSell17,649$6.31$111,365.19View SEC Filing  
3/18/2014Thomas KleinInsiderSell30,965$6.32$195,698.80View SEC Filing  
3/17/2014John VarianCEOSell10,000$6.03$60,300.00View SEC Filing  
2/18/2014John VarianCEOSell10,000$7.55$75,500.00View SEC Filing  
2/18/2014Paul RubinCMOSell6,000$7.55$45,300.00View SEC Filing  
1/21/2014Paul RubinCMOSell6,000$8.27$49,620.00View SEC Filing  
1/15/2014John VarianCEOSell10,000$8.28$82,800.00View SEC Filing  
1/9/2014Patrick Md Phd ScannonVPSell20,000$8.00$160,000.00View SEC Filing  
12/18/2013Paul RubinCMOSell6,000$5.67$34,020.00View SEC Filing  
12/16/2013John VarianCEOSell10,000$5.44$54,400.00View SEC Filing  
12/2/2013Patrick Md Phd ScannonVPSell20,000$6.00$120,000.00View SEC Filing  
11/27/2013Paul RubinCMOSell4,696$4.54$21,319.84View SEC Filing  
11/18/2013Paul RubinCMOSell1,304$4.08$5,320.32View SEC Filing  
11/15/2013John VarianCEOSell64,932$3.95$256,481.40View SEC Filing  
10/15/2013John VarianCEOSell10,000$4.60$46,000.00View SEC Filing  
9/18/2013Paul RubinCMOSell6,000$4.53$27,180.00View SEC Filing  
9/16/2013John VarianCEOSell10,000$4.59$45,900.00View SEC Filing  
8/19/2013Bros. Advisors Lp BakerDirectorBuy2,757,791$3.62$9,983,203.42View SEC Filing  
8/19/2013Paul RubinCMOSell6,000$3.74$22,440.00View SEC Filing  
8/15/2013John VarianCEOSell61,647$3.87$238,573.89View SEC Filing  
8/14/2013Fred KurlandCFOSell7,498$3.86$28,942.28View SEC Filing  
8/14/2013Patrick Md Phd ScannonVPSell6,002$3.86$23,167.72View SEC Filing  
8/14/2013Paul RubinCMOSell10,520$3.86$40,607.20View SEC Filing  
7/18/2013Paul D RubinCMOSell6,000$4.71$28,260.00View SEC Filing  
7/15/2013John VarianCEOSell10,000$4.81$48,100.00View SEC Filing  
5/29/2013Paul D RubinCMOSell1,797$4.16$7,475.52View SEC Filing  
5/20/2013Paul D RubinCMOSell6,000$0.54$3,240.00View SEC Filing  
11/14/2012Fred KurlandCFOSell9,111$2.56$23,324.16View SEC Filing  
11/14/2012John VarianCEOSell40,587$2.56$103,902.72View SEC Filing  
11/14/2012Patrick J Md Phd ScannonEVPSell8,773$2.56$22,458.88View SEC Filing  
10/29/2012Julian BakerDirectorBuy4,722,666$3.00$14,167,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for XOMA Corporation (NASDAQ:XOMA)
DateHeadline
News IconXOMA Corporation (NASDAQ:XOMA) Projected to Achieve EPS Of ... - Stock Observer (NASDAQ:XOMA)
www.thestockobserver.com - February 19 at 8:03 AM
marketexclusive.com logoXOMA CORPORATION (NASDAQ:XOMA) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:XOMA)
marketexclusive.com - February 17 at 5:18 PM
News IconIs The Sell-Side Predicting That XOMA Corporation (NASDAQ:XOMA) Will Move Higher? - Winfield Review (NASDAQ:XOMA)
winfieldreview.com - February 17 at 8:19 AM
News IconPulling Back The Curtain on XOMA Corporation (NASDAQ:XOMA): Analysts & Wall Street Chime In - Winfield Review (NASDAQ:XOMA)
winfieldreview.com - February 17 at 8:19 AM
finance.yahoo.com logoXOMA Appoints Matthew Perry to its Board of Directors - Yahoo Finance (NASDAQ:XOMA)
finance.yahoo.com - February 17 at 8:19 AM
biz.yahoo.com logoXOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Security (NASDAQ:XOMA)
biz.yahoo.com - February 17 at 8:19 AM
feeds.benzinga.com logoXOMA Appoints Matthew Perry to its Board of Directors (NASDAQ:XOMA)
feeds.benzinga.com - February 16 at 8:14 AM
nasdaq.com logoBiotechnology Stocks Showing Strong Move To The Upside (NASDAQ:XOMA)
www.nasdaq.com - February 15 at 7:01 AM
streetinsider.com logoXOMA (XOMA) Prices $25M Registered Offering of Common Stock and Convertible Preferred Stock (NASDAQ:XOMA)
www.streetinsider.com - February 14 at 7:11 AM
4-traders.com logoNetworkNewsBreaks – XOMA Corp. (NASDAQ: XOMA) Prices $25M Registered Offering; Shares Higher (NASDAQ:XOMA)
www.4-traders.com - February 14 at 7:11 AM
investopedia.com logoXoma Declares $25M Registered Offering (XOMA) (NASDAQ:XOMA)
www.investopedia.com - February 14 at 7:11 AM
News IconXOMA Corporation (XOMA) Stock: Gaining On Offering Pricing (NASDAQ:XOMA)
cnafinance.com - February 14 at 7:11 AM
us.rd.yahoo.com logoXOMA Announces Pricing of $25 Million Registered Offering of Common Stock and Convertible Preferred Stock (NASDAQ:XOMA)
us.rd.yahoo.com - February 14 at 7:11 AM
biz.yahoo.com logoXOMA CORP Files SEC form 8-K, Other Events (NASDAQ:XOMA)
us.rd.yahoo.com - February 14 at 7:11 AM
investopedia.com logoXoma Launches $25 Million Registered Offering (NASDAQ:XOMA)
www.investopedia.com - February 14 at 7:11 AM
feeds.benzinga.com logo18 Biggest Mid-Day Gainers For Monday (NASDAQ:XOMA)
feeds.benzinga.com - February 13 at 1:25 PM
seekingalpha.com logoXOMA prices $25M direct equity offering (NASDAQ:XOMA)
seekingalpha.com - February 13 at 7:21 AM
investornewswire.com logoXOMA Corporation (NASDAQ:XOMA) Per-Share Earnings At $-2.13 - Investor Newswire (NASDAQ:XOMA)
www.investornewswire.com - February 11 at 6:26 AM
News IconStock Tracker: Earnings & Estimates for XOMA Corporation (NASDAQ:XOMA) - Aiken Advocate (NASDAQ:XOMA)
aikenadvocate.com - February 2 at 6:57 AM
investopedia.com logoXOMA Reports Proof of Concept for New Drug (XOMA) | Investopedia - Investopedia (NASDAQ:XOMA)
www.investopedia.com - February 2 at 6:57 AM
News IconXoma Corp. (Nasdaq: XOMA) Rises on Proof-of-Concept - StockNewsUnion (NASDAQ:XOMA)
stocknewsunion.com - February 2 at 6:57 AM
investopedia.com logoXOMA Says Its Drug Candidate 358 Is Progressing (NASDAQ:XOMA)
www.investopedia.com - February 2 at 6:57 AM
reuters.com logoBRIEF-Xoma established proof-of-concept for its product candidate 358 in congenital hyperinsulinism and hypoglycemia post-bariatric surgery (NASDAQ:XOMA)
www.reuters.com - February 1 at 7:32 AM
finance.yahoo.com logoXOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery (NASDAQ:XOMA)
finance.yahoo.com - February 1 at 7:32 AM
finance.yahoo.com logo4:02 pm XOMA has established proof-of-concept for its product candidate 358 in congenital hyperinsulinism and hypoglycemia post-bariatric surgery; co will host a webcast and conference call today, January 31, 2017, at 2:00 p.m. PST (NASDAQ:XOMA)
finance.yahoo.com - February 1 at 7:32 AM
News IconBotulism Market 2016-2026 by Segmentation: Based on Product Application and Region (NASDAQ:XOMA)
reports.pr-inside.com - January 31 at 8:13 AM
News IconIs There Inherent Value in XOMA Corporation (NASDAQ:XOMA)? Analysts Delve Into The Stock - Wall Street Beacon (NASDAQ:XOMA)
wsbeacon.com - January 27 at 9:37 PM
News IconIndicator Level Summary for XOMA Corporation (XOMA) - Sherwood Daily (NASDAQ:XOMA)
sherwooddaily.com - January 27 at 4:14 PM
News IconAnalysts Peering Into Their Crystal Balls, What's the Sentiment on XOMA Corporation (NASDAQ:XOMA) - Wall Street Beacon (NASDAQ:XOMA)
wsbeacon.com - January 27 at 6:52 AM
News IconPeeling Back The Layers on XOMA Corporation (NASDAQ:XOMA): Sell-Side Weighs In - Wall Street Beacon (NASDAQ:XOMA)
wsbeacon.com - January 25 at 2:00 AM
News IconAnalysts Pounding The Pavement on XOMA Corporation (NASDAQ:XOMA): Consensus Update - Wall Street Beacon (NASDAQ:XOMA)
wsbeacon.com - January 24 at 3:57 PM
News IconDevling Into Shares of XOMA Corporation (NASDAQ:XOMA), What Are Analysts Predicting for 2017? - Wall Street Beacon (NASDAQ:XOMA)
wsbeacon.com - January 20 at 5:47 AM
streetinsider.com logoXOMA (XOMA) Says Servier Agreed to Amend Terms of Loan Agreement (NASDAQ:XOMA)
www.streetinsider.com - January 19 at 4:31 PM
reuters.com logoBRIEF-Xoma Corp says Servier agreed to amend terms of loan agreement - SEC filing (NASDAQ:XOMA)
uk.reuters.com - January 19 at 4:31 PM
4-traders.com logoXOMA CORP : Entry into a Material Definitive Agreement (form 8-K) (NASDAQ:XOMA)
www.4-traders.com - January 19 at 4:31 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: XOMA Corporation (NASDAQ:XOMA) - Wall Street Beacon (NASDAQ:XOMA)
wsbeacon.com - January 19 at 8:07 AM
streetinsider.com logoXOMA (XOMA) Says Servier Agreed to Amend Terms of Loan Agreement - StreetInsider.com (NASDAQ:XOMA)
www.streetinsider.com - January 18 at 6:12 AM
News IconNew Analyst Ratings On XOMA Corporation (XOMA) - NewsDen (NASDAQ:XOMA)
newsden.net - January 18 at 6:12 AM
News IconEarnings Fever Sweeping In, What Are Analysts Expecting From XOMA Corporation (NASDAQ:XOMA)? - Wall Street Beacon (NASDAQ:XOMA)
wsbeacon.com - January 18 at 6:12 AM
reuters.com logoBRIEF-Xoma Corp says Servier agreed to amend terms of loan agreement - SEC filing - Reuters (NASDAQ:XOMA)
www.reuters.com - January 18 at 6:12 AM
biz.yahoo.com logoXOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:XOMA)
biz.yahoo.com - January 18 at 6:12 AM
News IconWill The Needle Move For XOMA Corporation (NASDAQ:XOMA) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:XOMA)
wsbeacon.com - January 17 at 8:37 AM
News IconPrimed For An Earnings Beat? Sell-side Chimes in on XOMA Corporation (NASDAQ:XOMA) Stock - Wall Street Beacon (NASDAQ:XOMA)
wsbeacon.com - January 13 at 8:28 PM
News IconWall Street and Armchair Analysts Weigh in on XOMA Corporation (NASDAQ:XOMA) Heading Into The New Year - Wall Street Beacon (NASDAQ:XOMA)
wsbeacon.com - January 13 at 7:18 AM
streetinsider.com logoForm 4 XOMA Corp For: Jan 09 Filed by: Neal James R (NASDAQ:XOMA)
www.streetinsider.com - January 10 at 4:26 PM
News IconStock ABR XOMA Corporation (NASDAQ:XOMA) At 3 - Stock Observer (NASDAQ:XOMA)
www.thestockobserver.com - January 9 at 8:26 PM
News IconXOMA Corp XOMA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:XOMA)
www.bioportfolio.com - January 9 at 4:54 AM
marketexclusive.com logoAnalyst Activity – Wedbush Reiterates Neutral on XOMA Corporation (NASDAQ:XOMA) - Market Exclusive (NASDAQ:XOMA)
marketexclusive.com - January 7 at 6:35 AM
marketexclusive.com logoAnalyst Activity – Wedbush Reiterates Neutral on XOMA Corporation (NASDAQ:XOMA) (NASDAQ:XOMA)
marketexclusive.com - January 6 at 6:42 AM
News IconStock ABR Of XOMA Corporation (NASDAQ:XOMA) At 3 - Stock Observer (NASDAQ:XOMA)
www.thestockobserver.com - January 2 at 8:11 PM

Social

What is XOMA Corporation's stock symbol?

XOMA Corporation trades on the NASDAQ under the ticker symbol "XOMA."

Where is XOMA Corporation's stock going? Where will XOMA Corporation's stock price be in 2017?

6 brokers have issued 1 year target prices for XOMA Corporation's shares. Their forecasts range from $2.00 to $14.00. On average, they expect XOMA Corporation's stock price to reach $8.00 in the next year.

When will XOMA Corporation announce their earnings?

XOMA Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

What are analysts saying about XOMA Corporation stock?

Here are some recent quotes from research analysts about XOMA Corporation stock:

  • Cowen and Company analysts commented, "XOMA released additional data from its Phase II studies of XOMA 358 in patients." (2/1/2017)

  • According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (1/18/2017)

Who owns XOMA Corporation stock?

XOMA Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (1.26%). Company insiders that own XOMA Corporation stock include Bros Advisors Lp Baker, James R Neal, John Varian, Patrick J Md Phd Scannon and Paul D Rubin.

Who sold XOMA Corporation stock? Who is selling XOMA Corporation stock?

XOMA Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. Company insiders that have sold XOMA Corporation stock in the last year include James R Neal, John Varian, Patrick J Md Phd Scannon and Paul D Rubin.

How do I buy XOMA Corporation stock?

Shares of XOMA Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of XOMA Corporation stock cost?

One share of XOMA Corporation stock can currently be purchased for approximately $5.26.

XOMA Corporation (NASDAQ:XOMA) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for XOMA Corporation (NASDAQ:XOMA)

Earnings History Chart

Earnings by Quarter for XOMA Corporation (NASDAQ:XOMA)

Dividend History Chart

Dividend Payments by Quarter for XOMA Corporation (NASDAQ:XOMA)

Last Updated on 2/19/2017 by MarketBeat.com Staff